Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: A Taiwanese nationwide study

Clinical Infectious Diseases

Volumn 60, Issue 4, 2015, Pages 566-577

  Chou, Hsu Wen ^a   Wang, Jiun Ling ^b,c   Chang, Chia Hsuin ^a,c   Lai, Chao Lun ^a,c   Lai, Mei Shu ^a,c   Chan, K Arnold ^c,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

azithromycin; cardiovascular death; levofloxacin; moxifloxacin; ventricular arrhythmia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CIPROFLOXACIN; CLARITHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; COMORBIDITY; FEMALE; HUMAN; MALE; MORTALITY; RISK; STATISTICAL MODEL; TAIWAN;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; ARRHYTHMIAS, CARDIAC; AZITHROMYCIN; BETA-LACTAMASE INHIBITORS; CARDIOVASCULAR DISEASES; CIPROFLOXACIN; CLARITHROMYCIN; COMORBIDITY; FEMALE; FLUOROQUINOLONES; HUMANS; LEVOFLOXACIN; LOGISTIC MODELS; MALE; RISK; TAIWAN;

EID: 84922345621     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu914     Document Type: Article

References (32)

1. Owens RC Jr, Nolin TD. Antimicrobial-Associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006; 43:1603-11.
2. Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis 2012; 55:1457-65.
3. Shaffer DN, Singer SJ. Macrolide antibiotics and torsades de pointes postmarketing analysis. Available at: http://www.fda.gov/ohrms/dockets/ac/01/slides/3746s1.htm. Accessed 14 August 2001.
4. Owens RC Jr, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002; 22:663-8.
5. Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013; 346:f1235.
6. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881-90.
7. Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014; 12:121-7.
8. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368:1704-12.
9. Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014; 311:2199-208.
10. Giudicessi JR, Ackerman MJ. Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?. Cleve Clin J Med 2013; 80:539-44.
11. Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013; 368:1665-8.
12. Executive Yuan. Department of Health. Bureau of National Health, I. National Health Insurance in Taiwan 2011 annual report. 2011. Available at: http://www.nhi.gov.tw/English/webdata/webdata.aspx?. menu=11&menu-id=296&webdata-id=1942&WD-ID=296. Accessed 27 November 2014.
13. Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med 2008; 148:258-67.
14. Hennessy S, Leonard CE, Freeman CP, et al. Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf 2010; 19:555-62.
15. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying ventricular arrhythmias using administrative and claims data. Pharmacoepidemiol Drug Saf 2012; 21(suppl 1):148-53.
16. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158:280-7.
17. Bhattacharya S, Abebe K, Simon M, Saba S, Adelstein E. Role of cardiac resynchronization in end-stage heart failure patients requiring inotrope therapy. J Card Fail 2010; 16:931-7.
18. Spreeuwenberg MD, Bartak A, Croon MA, et al. The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care 2010; 48:166-74.
19. Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis 2013; 57: 971-80.
20. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137:1091-7.
21. Pessi T, Karhunen V, Karjalainen PP, et al. Bacterial signatures in thrombus aspirates of patients with myocardial infarction. Circulation 2013; 127:1219-28.
22. Guan X, Yang W, Sun X, et al. Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction. Inflamm Res 2012; 61:591-8.
23. Sakurai-Komada N, Iso H, Koike KA, et al. Association between Chlamydophila pneumoniae infection and risk of coronary heart disease for Japanese: the JPHC study. Atherosclerosis 2014; 233:338-42.
24. Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Association of Mycoplasma pneumoniae infection with coronary artery disease and its interaction with chlamydial infection. Atherosclerosis 2004; 176:139-44.
25. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007; 29:374-9.
26. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006; 11:52-6.
27. Hagiwara T, Satoh S, Kasai Y, Takasuna K. A comparative study of the various fluoroquinolone antibacterial agents on the cardiac action potential in guinea pig right ventricular myocardium. Jpn J Pharmacol 2001; 87:231-4.
28. Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+channel HERG. Mol Pharmacol 2001; 59:122-6.
29. Shah RR. Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?. Br J Clin Pharmacol 2013; 75:347-58.
30. Murakoshi N, Aonuma K. Epidemiology of arrhythmias and sudden cardiac death in Asia. Circ J 2013; 77:2419-31
31. Juang JM, Phan WL, Chen PC, et al. Brugada-type electrocardiogram in the Taiwanese population-is it a risk factor for sudden death?. J Formos Med Assoc 2011; 110:230-8
32. Simkó J, Csilek A, Karászi J, Lorincz I. Proarrhythmic potential of antimicrobial agents. Infection 2008; 36:194-206.